Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Alterity Therapeutics Ltd ADR (ATHE)

$4.51 -0.03 (-0.66%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	82.29M
Revenue (ttm)	0.00
Net Income (ttm)	-15.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	16,172
Avg Vol	16,312
Day's Range	N/A - N/A
Shares Out	18.13M
Stochastic %K	23%
Beta	0.27
Analysts	Strong Sell
Price Target	$12.33

Company Profile

Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clin...

Industry: Biotechnology

Sector: Healthcare

Phone: 61 3 9349 4906

Fax: 61 03 9349 4906

Website: alteritytherapeutics.com

Address:

500 Collins Street, Level 15, Melbourne, Australia

cfvk Sep. 8 at 6:06 PM

$ATHE someone is soaking up shares on bid. Pretty sure I saw 30k last week.

0 · Reply

Double__Down Sep. 7 at 11:51 PM

$ATHE let’s have ourselves a week!

0 · Reply

stckmuncher Sep. 7 at 9:38 PM

$ATHE $5+ by 2030

1 · Reply

stckmuncher Sep. 7 at 9:38 PM

$ATHE $25+

0 · Reply

cfvk Sep. 4 at 8:52 PM

$ATHE seen a decent size bid multiple times this week

0 · Reply

stckmuncher Sep. 3 at 9:30 AM

$ATHE 🚨🚨🚨 https://alteritytx.com/announcements/7716639

1 · Reply

GA09 Sep. 2 at 5:36 PM

$ATHE Wondering whether we get an update from the CEO on how discussions with pharma companies is progressing or whether we hear any positive news on partnership with pharma. A strategic partnership with pharma would indicate confidence in the efficacy and potential of 434.

0 · Reply

stckmuncher Sep. 1 at 6:57 PM

$ATHE 🚀🚀🚀🚀🚀🚀

0 · Reply

stckmuncher Sep. 1 at 6:57 PM

$ATHE Quit dicking around please…

0 · Reply

stckmuncher Aug. 31 at 2:03 PM

$ATHE $20 by year end…

0 · Reply

Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

ATHE

Alterity Therapeutics initiated with a Buy at JonesResearch

2026-06-29T20:30:18.000Z - 2 months ago

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

ATHE

Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026

May 7, 2026, 7:25 AM EDT - 4 months ago

Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy

ATHE

2026-04-22T11:44:01.000Z - 4 months ago

Alterity Therapeutics presents new data analyses from ATH434 trial

ATHE

Apr 22, 2026, 7:25 AM EDT - 4 months ago

Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology

ATHE

Alterity Therapeutics appoints Cunningham to Board of Directors

2026-04-17T11:39:13.000Z - 4 months ago

Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments

ATHE

Alterity Therapeutics Quarterly report: H1 2026

Feb 24, 2026, 6:00 PM EST - 6 months ago

Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Thu, 02 Oct 2025 07:35:00 -0400 - 11 months ago

Alterity Therapeutics to Deliver Multiple Presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders

Alterity Therapeutics Raises A$20.0 million in Strategic Placement

Mon, 08 Sep 2025 07:35:00 -0400 - 1 year ago

Alterity Therapeutics Reports Positive Topline Data from Open-Label Phase 2 Clinical Trial of ATH434 in Multiple System Atrophy

Alterity Therapeutics Announces Publication on Novel MRI Endpoint from the bioMUSE Natural History Study

Jul 24, 2025, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting

Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy

Mar 27, 2025, 7:25 AM EDT - 1 year ago

Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy

Alterity Therapeutics Transcript: Study Result

Jan 29, 2025, 8:01 PM EST - 1 year ago

Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy

Nov 19, 2024, 7:25 AM EST - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary

Nov 12, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434

Nov 6, 2024, 7:35 AM EST - 1 year ago

Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Sep 30, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer

Sep 26, 2024, 3:30 AM EDT - 1 year ago

Alterity Therapeutics Annual report: H2 2024

Sep 23, 2024, 7:35 AM EDT - 1 year ago

Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson's Disease and Movement Disorders®

Jul 31, 2024, 7:35 AM EDT - 2 years ago

Appendix 4C – Q4 FY24 Quarterly Cash Flow Report

cfvk Sep. 8 at 6:06 PM

$ATHE someone is soaking up shares on bid. Pretty sure I saw 30k last week.

0 · Reply

Double__Down Sep. 7 at 11:51 PM

$ATHE let’s have ourselves a week!

0 · Reply

stckmuncher Sep. 7 at 9:38 PM

$ATHE $5+ by 2030

1 · Reply

stckmuncher Sep. 7 at 9:38 PM

$ATHE $25+

0 · Reply

cfvk Sep. 4 at 8:52 PM

$ATHE seen a decent size bid multiple times this week

0 · Reply

stckmuncher Sep. 3 at 9:30 AM

$ATHE 🚨🚨🚨 https://alteritytx.com/announcements/7716639

1 · Reply

GA09 Sep. 2 at 5:36 PM

0 · Reply

stckmuncher Sep. 1 at 6:57 PM

$ATHE 🚀🚀🚀🚀🚀🚀

0 · Reply

stckmuncher Sep. 1 at 6:57 PM

$ATHE Quit dicking around please…

0 · Reply

stckmuncher Aug. 31 at 2:03 PM

$ATHE $20 by year end…

0 · Reply

stckmuncher Aug. 31 at 2:02 PM

$ATHE OPTIONS BABY!!!!!!!

0 · Reply

GA09 Aug. 31 at 1:20 PM

$ATHE Issuing options to raise cash ($4M - $8M). They are aggresively getting ready for a Phase 3 trial while having ongoing negotiations on partnership.

0 · Reply

RobGro Aug. 31 at 11:48 AM

$ATHE Looks like we have $55M+AU in the kitty to get us some way thru Ph3

0 · Reply

stckmuncher Aug. 29 at 10:02 PM

$ATHE GO UP YOU FUCK

0 · Reply

stckmuncher Aug. 29 at 10:02 PM

$ATHE MY DICK WENT LIMP…..

0 · Reply

GA09 Aug. 28 at 7:50 PM

$ATHE It needs a very strong catalyst to burst over $5. That is news on partnership or acquisition.

1 · Reply